228 related articles for article (PubMed ID: 21677003)
1. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry.
Bader-Meunier B; Decaluwe H; Barnerias C; Gherardi R; Quartier P; Faye A; Guigonis V; Pagnier A; Brochard K; Sibilia J; Gottenberg JE; Bodemer C;
J Rheumatol; 2011 Jul; 38(7):1436-40. PubMed ID: 21677003
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
Terrier B; Amoura Z; Ravaud P; Hachulla E; Jouenne R; Combe B; Bonnet C; Cacoub P; Cantagrel A; de Bandt M; Fain O; Fautrel B; Gaudin P; Godeau B; Harlé JR; Hot A; Kahn JE; Lambotte O; Larroche C; Léone J; Meyer O; Pallot-Prades B; Pertuiset E; Quartier P; Schaerverbeke T; Sibilia J; Somogyi A; Soubrier M; Vignon E; Bader-Meunier B; Mariette X; Gottenberg JE;
Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
[TBL] [Abstract][Full Text] [Related]
5. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology.
Wendling D; Dougados M; Berenbaum F; Brocq O; Schaeverbeke T; Mazieres B; Marcelli C; Leparc JM; Bertin P; Robin M; Sibilia J; Lafforgue P; Prati C; Combe B; Gottenberg JE;
J Rheumatol; 2012 Dec; 39(12):2327-31. PubMed ID: 22896028
[TBL] [Abstract][Full Text] [Related]
6. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
7. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry.
Puéchal X; Gottenberg JE; Berthelot JM; Gossec L; Meyer O; Morel J; Wendling D; de Bandt M; Houvenagel E; Jamard B; Lequerré T; Morel G; Richette P; Sellam J; Guillevin L; Mariette X;
Arthritis Care Res (Hoboken); 2012 Mar; 64(3):331-9. PubMed ID: 22076726
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry.
Mekinian A; Ravaud P; Hatron PY; Larroche C; Leone J; Gombert B; Hamidou M; Cantagrel A; Marcelli C; Rist S; Breban M; Launay D; Fain O; Gottenberg JE; Mariette X
Ann Rheum Dis; 2012 Jan; 71(1):84-7. PubMed ID: 21926185
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
Roll P; Ostermeier E; Haubitz M; Lovric S; Unger L; Holle J; Kötter I; Henes JC; Bergner R; Rubbert-Roth A; Specker C; Schulze-Koops H; Müller-Ladner U; Fleck M; Burmester GR; Hiepe F; Heitmann S; Aringer M; Fischer-Betz R; Dörner T; Tony HP
J Rheumatol; 2012 Nov; 39(11):2153-6. PubMed ID: 22984269
[TBL] [Abstract][Full Text] [Related]
10. The arthritis of inflammatory childhood myositis syndromes.
Tse S; Lubelsky S; Gordon M; Al Mayouf SM; Babyn PS; Laxer RM; Silverman ED; Schneider R; Feldman BM
J Rheumatol; 2001 Jan; 28(1):192-7. PubMed ID: 11196524
[TBL] [Abstract][Full Text] [Related]
11. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
12. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
Mariette X; Gottenberg JE; Ravaud P; Combe B
Rheumatology (Oxford); 2011 Jan; 50(1):222-9. PubMed ID: 21148156
[TBL] [Abstract][Full Text] [Related]
13. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
Reguiai Z; Tabary T; Maizières M; Bernard P
J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
[TBL] [Abstract][Full Text] [Related]
14. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.
Riley P; Maillard SM; Wedderburn LR; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2004 Apr; 43(4):491-6. PubMed ID: 14722349
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
[TBL] [Abstract][Full Text] [Related]
17. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use.
Chiu YE; Co DO
Pediatr Dermatol; 2011; 28(4):357-67. PubMed ID: 21793879
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry.
Couderc M; Gottenberg JE; Mariette X; Hachulla E; Sibilia J; Fain O; Hot A; Dougados M; Euller-Ziegler L; Bourgeois P; Larroche C; Tournadre A; Amoura Z; Mazières B; Arlet P; De Bandt M; Schaeverbeke T; Soubrier M
Rheumatology (Oxford); 2011 Dec; 50(12):2283-9. PubMed ID: 22019807
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence.
Narváez J; Ríos-Rodriguez V; de la Fuente D; Estrada P; López-Vives L; Gómez-Vaquero C; Nolla JM
Semin Arthritis Rheum; 2011 Dec; 41(3):364-72. PubMed ID: 21875742
[TBL] [Abstract][Full Text] [Related]
20. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry.
Godot S; Gottenberg JE; Paternotte S; Pane I; Combe B; Sibilia J; Flipo RM; Schaeverbeke T; Ravaud P; Toussirot E; Berenbaum F; Mariette X; Wendling D; Sellam J
Arthritis Care Res (Hoboken); 2013 Nov; 65(11):1874-9. PubMed ID: 23754822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
